's Hospit a l , Department of P e d i a t r i c s , Columbus, Ohio.
The Ohio S t a t e University College of Medicine, Children's Hospit a l , Department of P e d i a t r i c s , Columbus, Ohio.
Although used e x t e n s i v e l y i n Europe, t h e r e i s l i m i t e d pediat r i c c l i n i c a l experience with CXM i n t h e United S t a t e s . T h i r t y children, 4-43 mo i n age received CXM, 25 mglkg I V every 8 h r f o r p o t e n t i a l l y bacteremic s o f t t i s s u e i n f e c t i o n s of t h e f a c e , o r epi g l o t t i t i s . I n f e c t i o n s t r e a t e d included pre-septa1 (16) and bucc a l (12) c e l l u l i t i s and e p i g l o t t i t i s ( 2 ) . Blood c u l t u r e s were p o s i t i v e i n 18 p a t i e n t s : H. influenzae type b-13 (2 0-lactamase p o s i t i v e ) ; S. pneumoniae-4;and 8-lactamase p o s i t i v e , nontypable H. influenzae-1.
An a d d i t i o n a l 5 p a t i e n t s with buccal c e l l u l i t i s -had negative c u l t u r e s but H-influenzae type b a n t i g e n u r i a . A l l i s o l a t e s were s u s c e p t i b l e t o CXM. The median MBC f o r t h e blood c u l t u r e i s o l a t e s was 0.5 pg/ml (range 0.008-2.0 pg/ml). A good c l i n i c a l response was noted i n a l l p a t i e n t s and repeat blood cult u r e s performed on i n i t i a l l y bacteremic p a t i e n t s were s t e r i l e . The mean d u r a t i o n of CXM therapy was 4.631.2 days. A l l p a t i e n t s were discharged on an appropriate o r a l a n t i b i o t i c t o complete a 10 day course of therapy. There w e r e no c l i n i c a l a d v e r s e e f f e c t s o r breakthrough meningitis experienced during therapy with CXM. Lab abnormalitis encountered included a b s o l u t e granulocytopenia ( 4 ) ; thrombocytosis ( 3 ) ; and elevated l i v e r functions ( 2 ) . CXM appears t o be a s a f e and e f f e c t i v e therapy of p e d i a t r i c s o f t t i ssue i n f e c t i o n s due t o 5 influenzae and & pneumoniae.
Measurement of Antiviral Drugs Active Against
Varicella Zoster Virus (VZV) Using ELISA Directly on Infected Cells Superiority 0 ver Plaque-Reduction Assay (PRA). F.E. Berkowitz and M.J. Levin. Dept Pediatrics, University of Colorado Health Sciences Center, Denver, CO 80262.
The standard method f o r measuring antiviral activity against V Z V i s P R A. This has several disadvantages: 1) Subjective endpoint; 2) time and labor intensity; and 3) inability t o measure the druginduced changes in plaque size. We improved upon this method as follows: human embryonic lung fibroblasts in microtiter plates were infected with V Z V , antivirals were added, and 3 days l a t e r the monolayers were glutaraldehyde-fixed. V Z V antigen was quantitated in-situ using hyperimmune human globulin (VZIG) and peroxidaseconjugated goat anti-human IgG in a standard ELISA. Antigen representing 5 t o 10 plaques could be detected.
Dose-response curves f o r ELISA, PRA and infectious center assay were similar.
When the activity of 4 antivirals (acyclovir, trifluorothymidine, adenine arabinoside and bromovinyldeoxyuridine) were compared by ELISA and PRA the ID50's and the means of the coefficients of variation were lower by ELISA.
An inoculum effect was also demonstrated for 3 of the 4 drugs tested. The in-situ ELISA was found t o be superior t o conventional PRA because the endpoint measurement was objective, multiple replicates were easily performed with little extra time or effort, and there was less variability. I t i s quicker when 3 or more samples must be tested, and i s particularly In humans ACV diminishes the immune response to herpes simplex virus (HSV) and may therefore increase the severity of first recurrences. ACV may also diminish the long-term recurrence pattern and can prevent recurrences when taken prophylactically. To determine the effects on recurrence patterns, oral ACV (5 mg/ml in drinking water) was provided for 21 days beginning 12 hours a f t e r intravaginal HSV-2 inoculation in weanling Hartley gps. The severity of initial skin disease was decreased and 6/18 ACV-treated animals exhibited no skin lesions. Vaginal virus titers, however, were similar in both control and ACV treated groups. During t h e period from 14-21 days, while still receiving ACV, treated gps had similar rates of viral isolation and clinical recurrences which were similar in numbers but clinically milder than those seen in control animals. During ACV treatment blood ACV levels were .35 to 3.8 pg/ml. All HSV isolates remained sensitive to ACV. In the period immediately after ACV was discontinued (day 22-30) drugtreated gps had resurrencs that were similar in number, duration and severity t o control animals. Five of the 6 ACV-treated animals that had subclinical initial infection had either asymptomatic viral shedding (I) or clinically apparent disease (4) during this period. Animals followed t o day 60 had a similar number of recurrences whether or not they had received ACV. ACV treated animals did not have more severe disease immediately after therapy was discontinued nor a redrction in t h e number of long-term recurrences. Recent studies have suggested that the production of antibodies to specific herpes simplex virus (HSV) polypeptides c a n modify recurrent disease and b e affected by ACV therapy. We examined t h e sequential response t o HSV-2 polypeptides and t h e production of neutralizing antibodies following intravaginal HSV-2 inoculation of weanling Hartley guinea pigs. This response was then compared t o simultaneously infected animals who received ACV ( 5 mg/ml in drinking water) f o r 21 days. The initial response, seen a t 14 days in both ACV and control animals, was directed predominantly a t two nonglycosylated proteins of MW 40 and 43K. The response t o the major nucleocapsid protein (146K) was also seen initially on day I4 in the majority (9114) of control animals but not until day 21 (7/16), and in some cases day 28, in ACV recipients. The response to glycoprotein B and a number of other proteins between 70 and 90K was also delayed in ACV recipients. BY day 60 there was no apparent difference between ACV and control animals. Similarily, t h e mean titer of neutralizing antibody was significantly lower in ACV animals compared to controls on day 14 (2.8. vs. 5.8) (P c.025) and 21 (10.5 vs 29.5) (p c.05); however, by day 28 while titers were still lower (18.2 vs. 35.5) t h e difference was no longer significant. Control guinea pigs intravaginally inoculated with HSV-2 develop a characteristic antibody response while ACV-treated, HSV-2 infected guinea pigs developed similar but delayed antibody response. --
ANTIBODY RESPONSE OF HSV-2 GENITALLY INFECTED GUINEA PIGS: EFFECT OF ACYCLOVIR (ACV
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